Therapeutic Targets for Management of Periodontitis and Diabetes.

Abstract

The increasing incidence of diabetes mellitus (DM) and chronic periodontitis (CP) worldwide imposes a rethinking of individualized therapy for patients with both conditions. Central to bidirectional links between DM and CP is deregulated systemic inflammation and dysfunctional immune responses to altered-self and non-self. Control of blood glucose levels and metabolic imbalances associated with hyperglycemia in DM, and disruption of pathogenic subgingival biofilms in CP are currently the main therapeutic approaches for these conditions. Mounting evidence suggests the need to integrate immune modulatory therapeutics in treatment regimens that address the unresolved inflammation associated with DM and CP. The current review discusses the pathogenesis of DM and CP with emphasis on deregulated inflammation, current therapeutic approaches and the novel pro-resolution lipid mediators derived from Ω-3 polyunsaturated fatty acids.

• Authors: Corneliu Sima, Thomas E Van Dyke
• Journal: Current pharmaceutical design (Curr Pharm Des) Vol. 22 Issue 15 Pg. 2216-37 ( 2016) ISSN: 1873-4286 [Electronic] United Arab Emirates
• PMID: 26881443 (Publication Type: Journal Article, Review)

Chemical References

• Fatty Acids, Unsaturated

Topics

• Diabetes Mellitus (drug therapy)
• Fatty Acids, Unsaturated (therapeutic use)
• Humans
• Inflammation (drug therapy)
• Periodontitis (drug therapy)